Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors. (Q53464212)

http://europepmc.org/abstract/MED/26083553

14 May 2018

title

Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors. (English)

1 reference

http://europepmc.org/abstract/MED/26083553

14 May 2018

author

Juan José Ríos Martín

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

José Luis Rodríguez-Peralto

13 June 2020

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Erica Riveiro-Falkenbach

1

object named as

Erica Riveiro-Falkenbach

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Cándida A Villanueva

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

María C Garrido

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Yolanda Ruano

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Rosa M García-Martín

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Elena Godoy

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Pablo L Ortiz-Romero

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Angel Santos-Briz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

English

0 references

publication date

17 June 2015

1 reference

http://europepmc.org/abstract/MED/26083553

14 May 2018

published in

Journal of Investigative Dermatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

135

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

3078-3085

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26083553%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/jid.2015.229

13 June 2020

exact match

0 references

cites work

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

1 reference

12 December 2020

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

12 December 2020

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma

1 reference

12 December 2020

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

12 December 2020

Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility

1 reference

12 December 2020

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing

1 reference

12 December 2020

Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia

1 reference

12 December 2020

Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions

1 reference

12 December 2020

Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed.

1 reference

12 December 2020

Molecular platforms utilized to detect BRAF V600E mutation in melanoma

1 reference

12 December 2020

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

1 reference

12 December 2020

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

1 reference

12 December 2020

Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?

1 reference

12 December 2020

Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients.

1 reference

12 December 2020

Intrapatient homogeneity of BRAFV600E expression in melanoma.

1 reference

12 December 2020

Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression

1 reference

12 December 2020

Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma

1 reference

12 December 2020

Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays.

1 reference

12 December 2020

BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma

1 reference

12 December 2020

BRAF targeted therapy changes the treatment paradigm in melanoma

1 reference

12 December 2020

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

1 reference

12 December 2020

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies

1 reference

12 December 2020

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

12 December 2020

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

1 reference

12 December 2020

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

1 reference

12 December 2020

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

1 reference

12 December 2020

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

1 reference

12 December 2020

The Measurement of Observer Agreement for Categorical Data

1 reference

12 December 2020

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations

1 reference

12 December 2020

Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1

1 reference

12 December 2020

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.

1 reference

12 December 2020

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.

1 reference

12 December 2020

Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas

1 reference

12 December 2020